R&D channel feed

NGM Bio sub­ject of take-pri­vate bid by in­sti­tu­tion­al in­vestor The Col­umn Group

Last year
Deals

Long­board stock soars on heels of pos­i­tive topline da­ta for seizure med­ica­tion

Last year
Pharma

Anavex’s ex­per­i­men­tal drug fails Rett syn­drome study, stock falls

Last year

As­cle­tis’ Gan­nex re­ports pos­i­tive in­ter­im PhII NASH da­ta af­ter scrap­ping pre­vi­ous mid-stage R&D plans

Last year

Verona se­cures $400M fi­nanc­ing arrange­ment with Ox­ford, Her­cules as en­sifen­trine PDU­FA date inch­es clos­er

Last year
Financing

Zealand drug hit with CRL for ul­tra-rare dis­ease amid man­u­fac­tur­ing con­cerns, plans to re­sub­mit in 2024

Last year
Manufacturing

Cy­to­ki­net­ic­s' PhI­II car­diomy­opa­thy win sets up show­down with Bris­tol My­ers and sparks M&A spec­u­la­tion

Last year

Io­vance’s reg­is­tra­tional lung can­cer tri­al on hold af­ter pa­tient death

Last year
FDA+

FDA de­clines to grant Am­gen’s Lumakras full ap­proval in lung can­cer af­ter neg­a­tive ad­vi­so­ry com­mit­tee vote

Last year
FDA+

AlloVir to wind down PhI­II tri­als for fu­til­i­ty and will re­view strate­gic al­ter­na­tives

Last year

Tonix rais­es $144M in a di­rect of­fer­ing fol­low­ing pos­i­tive PhI­II da­ta for its fi­bromyal­gia drug

Last year
Financing

Im­muno­vant un­veils pos­i­tive ear­ly da­ta for PhII Graves' dis­ease drug

Last year

FDA hands CRL to Mer­ck­'s chron­ic cough drug over ef­fi­ca­cy ques­tions

Last year
FDA+

Sanofi pulls the plug on ADC af­ter lung can­cer PhI­II dis­ap­points

Last year

FDA en­cour­ages col­lab­o­ra­tion be­tween mon­o­clon­al an­ti­body spon­sors to keep pace with emerg­ing Covid vari­ants

Last year
Pharma
FDA+

Ar­genx scraps pro­gram in skin au­toim­mune dis­ease af­ter Vyv­gart Hytru­lo flunks an­oth­er PhI­II tri­al

Last year

Lil­ly, No­vo’s bet on heart dis­ease starts to take shape, and 2024 could be a piv­otal year for their GLP-1s 

Last year
In Focus

Pfiz­er no longer go­ing to con­duct in­ter­im analy­sis for Duchenne gene ther­a­py study by end of year

Last year

Com­pu­gen se­cures li­cens­ing deal with Gilead for IL-18 pro­tein an­ti­body can­cer pro­gram, with $60M up­front

Last year
Deals

Io­n­is di­vests com­mer­cial EU rights for rare dis­ease can­di­date to Ot­su­ka for $65M up­front

Last year
Deals

Atara Bio­ther­a­peu­tics to lay off 73 Cal­i­for­nia em­ploy­ees by the end of the year

Last year
Pharma

Covid biotech’s stock jumps af­ter pos­i­tive ear­ly PhI­II mon­o­clon­al an­ti­body da­ta re­veal

Last year

Point Bio­phar­ma’s close­ly watched prostate can­cer ra­dio­phar­ma­ceu­ti­cal study dis­ap­points, Lil­ly again ex­tends of­fer

Last year

No­vo Nordisk Foun­da­tion to launch $260M vac­cine ini­tia­tive in ear­ly 2024

Last year
Manufacturing
First page Previous page 56575859606162 Next page Last page
A service from the Financial Times